Melanoma Clinical Trials in Tennessee

Showing 181-200 of 285 trials

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic Melanoma+1 more

Bristol-Myers Squibb395 participantsStarted Oct 2008

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +10 more locations

COMPLETEDPhase 229 miles

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938

The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab

Advanced or Metastatic Melanoma

Bristol-Myers Squibb138 participantsStarted Apr 2013

Tampa, Florida, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +8 more locations

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Melanoma Trials in Other Cities

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Other Conditions in Tennessee